RePORT Brazil is a joint venture among the Departamento de Ciencia e Tecnologia/Ministério da Saude (DECIT), the U.S. Office of AIDS Research and NIAID, co-funding a team of Brazil- and U.S.-based investigators to enroll people with active and latent TB in Brazil. Four sites in Rio de Janeiro, one in Manaus, and one in Salvador were selected to enroll up to 900 active TB cases and 2,700 close contacts of those TB cases.  Vanderbilt University is the U.S.-based academic partner working with RePORT Brazil.  RePORT Brazil is led by a scientific and steering committee composed of researchers and members of NIH and DECIT, who will provide leadership, governance, and guidance to the consortium.

 

RePORT Brazil consortium sites also represent a diverse population and are enrolling into a single protocol, which is harmonized with the RePORT International Common Protocol. Sites will recruit sputum culture positive adults to observe the outcome of TB patients as well as the occurrence of TB among contacts with and without evidence of LTBI. Persons with LTBI will be offered isoniazid per Brazilian guidelines, while those who are tuberculin skin testing (TST) or interferon-gamma release assay (IGRA) negative will not receive treatment. The RePORT Brazil biorepository will be in Salvador at the Instituto Brasileiro de Reabilitação (IBR), where seven freezers and two liquid nitrogen containers will be used to store samples.